HIV-1
Clinical trials for HIV-1 explained in plain language.
Never miss a new study
Get alerted when new HIV-1 trials appear
Sign up with your email to follow new studies for HIV-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a Two-Drug HIV pill be enough for transgender women?
Disease control Recruiting nowThis study is for transgender women with HIV who are already on a stable three-drug regimen. It tests switching to a simpler two-drug combination (dolutegravir plus lamivudine) to see if it keeps the virus under control. About 50 participants will take the two-drug pill for 48 we…
Matched conditions: HIV-1
Phase: PHASE4 • Sponsor: UBATEC • Aim: Disease control
Last updated May 26, 2026 03:43 UTC
-
Can a leukemia drug flush out HIV's last hiding spots?
Disease control Recruiting nowThis early-stage study tests whether adding the drug venetoclax to standard HIV treatment can help kill cells that harbor dormant HIV. The goal is to shrink the hidden virus reservoir, which is the main barrier to a cure. About 38 adults newly starting HIV therapy will receive ve…
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: Thomas Aagaard Rasmussen • Aim: Disease control
Last updated May 26, 2026 03:32 UTC
-
Engineered immune cells aim to keep HIV in check without daily pills
Disease control Recruiting nowThis study tests a new treatment for people with HIV that uses their own immune cells, modified to recognize and attack HIV. The goal is to see if these special cells can stay active in the body and help control the virus, possibly allowing participants to stop daily antiretrovir…
Matched conditions: HIV-1
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
New antibody combo tested in HIV-Exposed infants
Disease control Recruiting nowThis study is testing whether giving two powerful antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV is safe and how long they stay in the body. About 48 infants will receive one or two doses soon after birth. The goal is to help control HIV, not cure it, and t…
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 19, 2026 11:47 UTC